Join us on May 18th for this symposium!

During this symposium, 4 world-renowned speakers in the NAFLD/NASH field will share their research, from new molecular insights, to novel targets for therapies against NASH and NAFLD-fibrosis. There will also be short talks from young investigators, sure to inspire your research!

For the unique opportunity to speak face-to-face with our speakers, you may sign up for the Meet-the-expert lunch.

This event is organized by the AGEM research institute in collaboration with the NAFLD-NL consortium: Onno Holleboom, Maarten Tushuizen, Saskia van Mil, Eveline Bruinstroop, Anne-Marieke van Dijk and Anne Linde Mak.

We hope to see you there!

Dates and location

WEDNESDAY
May 18th, 2022


Meet-the-expert Lunch
13:00h - 14:00h

Symposium
15:00h - 21:00h

Amsterdam UMC location AMC

Amsterdam UMC Lecture Hall 5

People meeting via ZOOM

Via ZOOM

Registration

Attending the symposium is free of charge, however registration is mandatory. Sign up here: https://forms.office.com/r/JLNa038nDZ

Program

13:00 - 14:00h Meet-the-expert Lunch

15:00 - 15:30h Registration 
15:30 - 15:40h Opening by Onno Holleboom and Eveline Bruinstroop
15:40 - 16:05h Stefano Romeo - PSD3 as a promising therapeutic
target against fatty liver disease 
16:15 - 16:40h Stan van de Graaf - Hepatic bile acid uptake as a target to halt the fatty liver epidemic
Coffee break
17:15 - 18:10h Short talks by 4 young researchers: Milena Schönke (LUMC),
Willemien van Zwol (UMCG), Stijn Meijnikman (AMC) and Dyonne Vos (UMCG)
Dinner
19:05 - 19:30h Paul Yen - Novel therapies for NASH with natural compounds
19:35 - 20:00h Patrick Rensen - Hormones to comBAT NAFLD
20:05 - 20:30h Closing remarks
Drinks

Speakers

Prof. dr. Paul Yen

Prof. Paul Yen

Duke-NUS Medical School and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program in Singapore

"Novel therapies for NASH with natural compounds" 
Dr. Yen is Professor at Duke-NUS Graduate Medical School in Singapore and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program. He obtained his M.D. from Johns Hopkins, completed residency in internal medicine at University of Chicago, and fellowship training in endocrinology at NIH. He has served on the editorial boards of Endocrinology, Molecular Endocrinology, and Thyroid. He is the recipient of the 2020 AOTA Nagataki Fujifilm Prize for his contributions to clinical and basic thyroid research.  His research interests include endocrine regulation of transcription, autophagy, and lipid metabolism in normal and disease states such as non-alcoholic fatty liver disease, GSD1a, Citrin deficiency, diabetes and obesity. 
Stefano Romeo

Prof. Stefano Romeo

Professor in Molecular and Clinical Medicine at the Sahlgrenska Academy in the Institute of Medicine at Gothenburg University and Senior Consultant in Endocrinology and metabolism at Sahlgrenska University Hospital in Gothenburg Sweden.

"PSD3 as a promising therapeutic
target against fatty liver disease"

Stefano Romeo is Professor in Molecular and Clinical Medicine at the Sahlgrenska Academy in the Institute of Medicine at Gothenburg University and Senior Consultant in Endocrinology and metabolism at Sahlgrenska University Hospital in Gothenburg. 
Dr. Romeo’s main research focus is the role of genetic variants in modulating metabolic liver disease and serum lipid levels. His research field ranges from genetic association studies in large cohorts to understanding molecular mechanisms underlying the genetic associations. His main clinical commitment is to drive the Lipid Clinic. 

Stan van de Graaf

Prof. Stan van de Graaf

Professor of Experimental Hepatology and Metabolism at the Amsterdam UMC and co-director of the research institute Amsterdam Gastroenterology, Endocrinology, Metabolism (AGEM) at UMC, Amsterdam The Netherlands.

"Hepatic bile acid uptake as a target to halt the fatty liver epidemic"

Stan van de Graaf recently received a VICI grant to continue and broaden his research line on NAFLD. His group recently identified the hepatic bile acid uptake transporter NTCP (Na/taurocholate Cotransporting Polypeptide) as a safe and efficient target to enhance and prolong bile acid signalling using the body’s own bile acid pool. NTCP inhibition reduces the amount of hepatic fat in high-calorie feeding conditions and independently also leads to dampening of inflammation, and therefore could be a promising new target to treat NAFLD.

Patrick Rensen

Prof. Patrick Rensen

Professor of Endocrinology at the Leiden University Medical Center Leiden (LUMC) in Leiden, The Netherlands.

"Hormones to comBAT NAFLD"


 


Prof. Patrick Rensen’s lab mainly focuses on the role of energy metabolism in cardiometabolic diseases including obesity, NASH and atherosclerotic cardiovascular disease. To this end, intervention studies in metabolically vulnerable populations are combined with mechanistic studies in APOE*3-Leiden.CETP mice, an in-house unique model for human cardiometabolic diseases.

Organization

Organized by the AGEM research institute in collaboration with the Dutch NAFLD-NL consortium.

Onno Holleboom
Eveline Bruinstroop
Anne-Marieke van Dijk
Anne Linde Mak

AGEM organizers:

Eva Dirkx
Linda van den Noord
For questions contact AGEM (agem@amsterdamumc.nl)

Advisors:

Prof. Saskia van Mil, UMC
Dr. Maarten Tushuizen, LUMC